10:06 AM EDT, 06/24/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Monday the first patient has been dosed in a phase 1/2 trial assessing Allocetra injection in patients with basal thumb joint osteoarthritis.

The study intends to recruit up to 46 patients, with the efficacy endpoints including change from baseline in pain and function for up to one year after treatment, and the primary safety endpoint measuring the frequency and severity of adverse events and serious adverse events, the company said.

Shares of Enlivex were down 2.2% in recent trading.

Price: 1.33, Change: -0.03, Percent Change: -2.21